Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma

Breast cancer 1 antigen (BRCA 1) and breast cancer 2 antigen (BRCA2) genes play a significant role in deoxyribonucleic acid (DNA) repair by means of interstrand crosslink repair, and deleterious germline mutations of these are responsible for most hereditary breast and ovarian cancers. Therapeutic s...

Descripción completa

Detalles Bibliográficos
Autores principales: Conroy, Michael, Borad, Mitesh J, Bryce, Alan H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613928/
https://www.ncbi.nlm.nih.gov/pubmed/28959512
http://dx.doi.org/10.7759/cureus.1517
Descripción
Sumario:Breast cancer 1 antigen (BRCA 1) and breast cancer 2 antigen (BRCA2) genes play a significant role in deoxyribonucleic acid (DNA) repair by means of interstrand crosslink repair, and deleterious germline mutations of these are responsible for most hereditary breast and ovarian cancers. Therapeutic strategies which specifically target interstrand crosslink repair can therefore be helpful in patients with harmful mutations. We describe two patients with advanced ovarian cancer and deleterious BRCA1 mutations who were treated with TH-302, a hypoxia-activated alkylating agent.

Ejemplares similares